(Q33388534)

26 July 2017

title

Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

X S Chen

1

1 reference

26 July 2017

X Q Nie

2

1 reference

26 July 2017

C M Chen

3

1 reference

26 July 2017

J Y Wu

4

1 reference

26 July 2017

J Wu

5

1 reference

26 July 2017

J S Lu

6

1 reference

26 July 2017

Z M Shao

7

1 reference

26 July 2017

Z Z Shen

8

1 reference

26 July 2017

K W Shen

9

1 reference

26 July 2017

publication date

8 March 2010

1 reference

26 July 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Annals of Oncology

1 reference

26 July 2017

volume

21

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

961-967

1 reference

26 July 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

The resurgence of platinum-based cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Carboplatin in combination therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

HER2/neu in systemic therapy for women with breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Letter: Creatinine clearance: bedside estimate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

HER-2 and topoisomerase II as predictors of response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ041

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ041

1 reference

26 July 2017

1 reference